The first patient has been dosed in the phase two study of PR022 (hypochlorous acid, Realm Therapeutics), a topical gel treatment for patients with atopic dermatitis. Top line data from the trial is expected in the third quarter of 2018, according to a news release.
The study is a randomized, double-blind, multicenter, vehicle-controlled, parallel-group trial including approximately 120 adult patients with mild-to-moderate atopic dermatitis. The study is being conducted in the United States.
The trial will evaluate Eczema Area and Severity Index scores, Investigator Global Assessment, pruritus and quality of life.
“Recently published peer-reviewed research has demonstrated PR022’s ability to prevent the development of atopic dermatitis-like lesions, reduce existing lesions and associated scratching, and reduce the inflammatory response,” Alex Martin, Realm CEO, said in a statement. “PR022 could offer an important alternative to patients suffering from atopic dermatitis and we are very excited about the potential of this new therapy.”